BIOCORP Signs Distribution Agreement for Mallya Technology With Roche Diabetes Care France
30.6.2020 08:30:00 EEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, announces today the signature of a distribution contract for its Mallya connected device with Roche Diabetes Care France.
As part of the agreement, Roche Diabetes Care France will distribute Mallya to pharmacies in France. This medical device is an intelligent 2-year reusable injector pen sensor that is compatible with the majority of insulin injection pens, both disposable and reusable. It automatically collects the insulin dose delivered with near 100% accuracy.
In the future, Mallya will also be part of the RocheDiabetes ecosystem consisting of connected blood glucose meters (Accu-Chek Mobile, Accu-Chek Guide) and digital solutions for better patients care.
Gluci-Chek is a smartphone application regularly used by nearly 60,000 diabetic patients in France. It brings together three major functionalities for personalized diabetes management: a carbohydrate calculation tool with visualization of portions on the plate, a self-monitoring glycemic logbook and a graphic visualization of glycemic results.
Thanks to Mallya, the patient will no longer have to manually report the insulin doses injected in the future since, once the sensor is paired with the Gluci-Chek application, the data will be automatically reported and displayed in the blood glucose monitoring logbook, regardless of the insulin pen1.
Frédéric Jacquey, President of Roche Diabetes Care France: “The signature of this agreement with Biocorp represents a fundamental step in the development of our ecosystem to improve the care of diabetic patients and their exchanges with healthcare professionals. With innovative technology like Mallya, we will soon be able to offer a unique offering for optimal patient care that integrates blood glucose data from our meters via Gluci-Chek and automatic insulin data via Mallya.”
Éric Dessertenne, CEO of BIOCORP: “Roche is the second pharmaceutical giant to integrate our Mallya connected device for optimal monitoring of diabetic patients into its commercial offer. I would like to thank the teams at Roche Diabetes Care France for their responsiveness over the last few weeks. This new structuring agreement confirms the ambitions presented to all our shareholders in early 2020 on the market of digitalization of diabetes and the considerable commercial potential of Mallya. With a partner of the calibre of Roche, we are confident that a large number of diabetics will quickly be able to benefit from the real benefits offered by Mallya on the secure monitoring of their daily insulin intake."
ABOUT DE ROCHE DIABETES CARE FRANCE
Roche Diabetes Care is a healthcare company specializing in diabetes. For more than 40 years, it has been designing solutions to meet the needs of both patients and healthcare professionals: medical devices (blood glucose meters, lancing devices, insulin pumps), services (information and therapeutic education support) and digital solutions (applications, platform for sharing blood glucose data between patients and healthcare professionals). By creating an ecosystem connecting medical devices and digital solutions, Roche Diabetes Care is paving the way for personalized diabetes management with the aim of facilitating and optimizing the management and monitoring of this complex disease.
Roche Diabetes Care France is a subsidiary of the Roche Group in France, alongside Roche SAS France and Roche Diagnostics France. For more information, please visit www.roche.fr.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
Follow us on Twitter @BIOCORPSystems
1 SoloStar de Sanofi – KwikPen de Eli Lilly – FlexPen de Novo Nordisk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005362/en/
Contact information
BIOCORP CONTACTS
Sylvaine Dessard
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
ROCHE DIABETES CARE FRANCE CONTACTS
Myriam Hamza
rochediabpresse@havas.com
+33 (0)6 45 87 46 51
Raphaële Badel
Raphaele.badel@roche.com
+33 (0)7 77 34 60 59
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GTN and Solidus Labs Announce Landmark Surveillance Partnership23.9.2026 16:00:00 EEST | Press release
GTN, the global fintech, and Solidus Labs, the category-definer in multidimensional market integrity, today announced a landmark partnership that deploys Solidus Labs' HALO platform across GTN's operations. Under the partnership, HALO is deployed across GTN's global order book, delivering integrated trade surveillance and transaction monitoring across equities, fixed income, derivatives, FX and digital/crypto assets. This means for brokers, banks, asset managers and fintechs, the era of surveillance as a barrier to market participation is over. Beyond GTN's internal compliance operations, this partnership introduces a surveillance layer that lets GTN's 500+ clients access dedicated HALO tenants through GTN's infrastructure. This embeds institutional-grade surveillance capabilities into the infrastructure that those firms already run their business on. Rather than each client independently procuring, integrating and running a surveillance stack, GTN's model lets firms across its institu
SS&C Technologies Unveils Portfolio of AI-Enabled Enhancements; Debuts Six-Part Agentic Blueprint Docuseries at SS&C Deliver23.9.2026 16:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today unveiled a suite of next-generation solutions at its annual SS&C Deliver 2026 conference. More than 1,100 leaders from the financial services and healthcare industries gathered in Orlando, Florida, to learn how SS&C is optimizing business workflows with AI-enabled services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923521682/en/ A core technology set spanning wealth, retirement, alternatives and asset management is built on the SS&C AI Gateway governance platform. SS&C WorkHQ, the company’s award-winning agentic orchestration platform, enables interoperability across these solutions. SS&C also debuted the six-part The Blueprint: Customer Zero docuseries, a behind-the-scenes look at how SS&C is running the same agentic transformation it is now bringing to its 23,000 clients. "Agentic AI is challenging enterprises. The technology moves fast, the governance stakes ar
Corient Expands to Cayman Islands with Acquisition of FortCay Family Office Advisory23.9.2026 16:00:00 EEST | Press release
Corient, the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net-worth and high-net-worth clients, today announced the addition of FortCay Family Advisory (“FortCay”), a Cayman Islands wealth manager and multi-family office. FortCay, founded by Billy Harty and Matt Houghton, serves 14 ultra-high-net-worth families representing approximately US$2.6 billion in client assets, providing comprehensive wealth management, estate planning and family office services. The acquisition establishes Corient in the Cayman Islands, a leading international financial center and important hub for private wealth, extending the firm’s reach in a strategically important market. “A meaningful share of the world’s most complex family wealth is structured and administered in the Cayman Islands,” said Kurt MacAlpine, Founding Partner and Chief Executive Officer of Corient. “Many of our clients live, work, and invest across borders – establishing a presence in Cayman deepens
Principal Asset Management ® and Longevity Partners Launch REsponsible Asset Solutions to Scale Real Estate Decarbonization Strategies23.9.2026 16:00:00 EEST | Press release
Principal Asset Management® and Longevity Partners today announced the launch of REsponsible Asset Solutions (RAS), a new platform designed to help institutional real estate owners identify, underwrite, and execute decarbonization initiatives that improve building performance, reduce energy consumption and enhance long-term asset value while meeting investment return objectives. REsponsible Asset Solutions brings together the institutional investment expertise of Principal Asset Management's dedicated real estate platform, a top-10 global real estate manager1 with $108 billion in assets under management2 and more than 65 years of experience, and Longevity Partners' engineering, procurement, and implementation capabilities. By combining deep real estate investment knowledge with technical decarbonization expertise, RAS provides scalable, value-enhancing strategies that help clients advance sustainability objectives while supporting long-term asset value. “Many institutional investors ha
The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women23.9.2026 15:30:00 EEST | Press release
The Estée Lauder Companies today announced a new five-year commitment to the Breast Cancer Research Foundation to establish the Global Research Initiative on Breast Cancer in Younger Women. This first-of-its-kind research coalition will address the alarming global rise in breast cancer diagnoses among younger women, building on more than three decades of partnership between The Estée Lauder Companies and the Breast Cancer Research Foundation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923337773/en/ The $15 millioncommitment from The Estée Lauder Companies Charitable Foundation is designed to confront an urgent and significantly underfunded need. Diagnoses among women under age 45 increased by 11 percent from 2012 to 2022,1 while an estimated only 0.6 percent of breast cancer research funding since 2020 has focused on younger women. Breast cancer in younger women is more likely to be diagnosed at a later stage and to b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom